Systemic membrane defect and the inhibition of lymphocyte capping in XXXX .

@entity1 @entity1169 @entity17388 @entity2769 @entity1388 @entity2644 @entity1555 @entity701 @entity460 @entity941 @entity11119
Eight reversible inhibitors were used to study decreases in lymphocyte capping in @entity1 with @entity1555 ( @entity1555 ) when compared to controls. The inhibitors included @entity701 , @entity2644 , @entity460 ionophore, @entity11119 , @entity1169 , @entity17388 , @entity1388 and @entity2769 . All of these inhibitors disrupt cap formation. Mononuclear leukocytes from @entity1555 @entity1 and controls were isolated from whole blood, incubated with @entity941 -conjugated polyvalent antisera and inhibitor, induced to form caps, and the caps counted using a fluorescent microscope. Cell viabilities and morphology were assessed. After removal of inhibitor, the cells were recounted. All of the inhibitors significantly lowered capping in controls (p less than 0.001), but this effect was seen with only four out of the eight inhibitors in @entity1555 @entity1 . @entity17388 and @entity2769 were less inhibitory in @entity1 (p less than 0.005, p greater than 0.05, and p greater than 0.05 respectively) while capping in @entity1 was not inhibited by @entity1388 and @entity701 (p greater than 0.5). The lack of @entity701 inhibition suggests that the differences in capping between @entity1555 @entity1 and controls may lie within the membrane itself, rather than its associated components (i.e. cytoskeletal network), and that the defect occurs toward the beginning of the capping sequence.
